Compare DaVita, Inc. with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 2.01% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Negative results in Jun 25
3
Risky - Negative Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 7,505 Million (Small Cap)
10.00
NA
0.00%
-16.89
-181.54%
-13.12
Revenue and Profits:
Net Sales:
3,420 Million
(Quarterly Results - Sep 2025)
Net Profit:
240 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.41%
0%
18.41%
6 Months
1.82%
0%
1.82%
1 Year
-19.9%
0%
-19.9%
2 Years
27.74%
0%
27.74%
3 Years
66.19%
0%
66.19%
4 Years
29.93%
0%
29.93%
5 Years
29.69%
0%
29.69%
DaVita, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.69%
EBIT Growth (5y)
2.01%
EBIT to Interest (avg)
4.56
Debt to EBITDA (avg)
3.65
Net Debt to Equity (avg)
-35.01
Sales to Capital Employed (avg)
1.27
Tax Ratio
18.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.83%
ROCE (avg)
17.82%
ROE (avg)
106.77%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
-42.98
EV to EBIT
10.70
EV to EBITDA
7.83
EV to Capital Employed
2.29
EV to Sales
1.61
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
21.42%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 110 Schemes (19.62%)
Foreign Institutions
Held by 310 Foreign Institutions (11.88%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
3,420.20
3,379.50
1.20%
Operating Profit (PBDIT) excl Other Income
673.10
705.20
-4.55%
Interest
148.70
144.00
3.26%
Exceptional Items
-5.20
0.00
Consolidate Net Profit
240.20
275.20
-12.72%
Operating Profit Margin (Excl OI)
144.90%
157.00%
-1.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 1.20% vs 4.84% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -12.72% vs 18.52% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
12,815.50
12,140.10
5.56%
Operating Profit (PBDIT) excl Other Income
2,678.70
2,346.40
14.16%
Interest
412.30
295.00
39.76%
Exceptional Items
89.70
-22.90
491.70%
Consolidate Net Profit
1,250.70
957.00
30.69%
Operating Profit Margin (Excl OI)
152.50%
131.90%
2.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.56% vs 4.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 30.69% vs 24.58% in Dec 2023
About DaVita, Inc. 
DaVita, Inc.
Pharmaceuticals & Biotechnology
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
Company Coordinates 
Company Details
2000 16th St , DENVER CO : 80202-5158
Registrar Details






